Although angiosarcoma is an EC-derived tumor and over-expresses both VEGF-A and VEGF receptors (VEGFRs), the effect of anti-VEGF reagents including Bevacizumab and Sorafenib are limited55,56. The gene discussed is VEGFA; the disease is neoplasm.